Sun Pharmaceutical Industries Limited has informed the Exchange about Transcript
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma reported Q4 FY26 consolidated sales of INR 145,598 million (up 13.6% YoY) with gross margin at 80.8%. However, EBITDA margin declined to 27.1% from 28.7% in Q4 FY25 and 31.9% in Q3 FY26, due to lower milestone income, reduced Revlimid contribution, and higher spending in certain geographies including the US. Full year FY26 sales were INR 582 billion (11.9% growth) with EBITDA margin of 30.3%. The company declared total dividend of INR 16 per share. Innovative Medicines (Ilumya-led) grew 20.1% in Q4 and crossed $1 billion in the US for the first time. The company guided for high single-digit revenue growth and 6-7% R&D spend for FY27, but did not provide margin guidance. The pending Organon acquisition is expected to close in Q4 FY27.
The sequential margin decline in Q4 is a near-term concern, though management expects some cost normalization. The company maintained its dividend and guided for steady revenue growth, with key future catalysts being the Organon acquisition and new product launches (UNLOXCYT, LEQSELVI).